Table I.

Ongoing clinical trials for Entrectinib and Larotrectinib in different types of cancers.

NCT identifier	Drug	Phase	Cancer type	Status
NCT02568267	Entrectinib	II	Breast cancer, cholangiocarcinoma, colorectal cancer, head and neck neoplasms, lymphoma, large-cell, anaplastic, melanoma, neuroendocrine tumors, non-small cell lung cancer, ovarian cancer, pancreatic cancer, papillary thyroid cancer, primary brain tumors, renal cell carcinoma, sarcomas, salivary gland cancers, and adult solid tumor	Recruiting
NCT03330990	Entrectinib	I	Advanced solid tumor	Completed
NCT02650401	Entrectinib	I	Solid tumors, CNS tumors, and neuroblastoma	Recruiting
NCT02097810	Entrectinib	I	Locally advanced solid tumors, metastatic solid tumors	Active, not recruiting
NCT02587650	Entrectinib	II	ALK fusion protein expression, BRAF wt Allele, invasive skin melanoma, MET fusion gene positive, NRAS wt Allele, NTRK1 fusion positive, NTRK2 fusion positive, NTRK3 fusion positive, RET fusion positive, ROS1 fusion positive, stage III cutaneous melanoma AJCC v7, stage IIIA cutaneous melanoma AJCC v7, stage IIIB cutaneous melanoma AJCC v7, stage IIIC cutaneous melanoma AJCC v7, and stage IV cutaneous melanoma AJCC v6 and v7	Recruiting
NCT02576431	Larotrectinib	II	Non-small-cell lung carcinoma, thyroid neoplasms, sarcoma, colorectal neoplasms, salivary gland neoplasms, biliary tract neoplasms, brain neoplasm, primary, carcinoma, ductal, breast, melanoma, solid tumors, glioblastoma, bile duct neoplasms, astrocytoma, head and neck squamous cell carcinoma, pontine glioma, pancreatic neoplasms, ovarian neoplasms, renal cell carcinoma, cholangiocarcinoma, bronchogenic carcinoma, bronchial neoplasms, lung neoplasms, respiratory tract neoplasms, thoracic neoplasms, neoplasms, nerve tissue, nevi and melanomas	Recruiting
NCT02637687	Larotrectinib	I and II	Neoplasms, central nervous system neoplasms	Recruiting
NCT03213704	Larotrectinib	II	Advanced malignant solid neoplasm, malignant glioma, ann arbor stage III childhood non-hodgkin lymphoma, ann arbor stage IV childhood non-hodgkin lymphoma, malignant glioma, NTRK1 fusion positive, NTRK2 fusion positive, NTRK3 fusion positive, recurrent central nervous system neoplasm, recurrent childhood ependymoma, recurrent childhood malignant germ cell tumor, recurrent childhood medulloblastoma, recurrent childhood non-hodgkin lymphoma, recurrent childhood rhabdomyosarcoma, recurrent childhood soft tissue sarcoma, recurrent ewing sarcoma, recurrent glioma, recurrent hepatoblastoma, recurrent langerhans cell histiocytosis, recurrent malignant solid neoplasm, recurrent neuroblastoma, recurrent osteosarcoma, recurrent peripheral primitive neuroectodermal tumor, refractory central nervous system neoplasm, refractory childhood malignant germ cell tumor, refractory langerhans cell histiocytosis, refractory malignant solid neoplasm, refractory neuroblastoma, refractory non-hodgkin lymphoma, rhabdoid tumor, stage III osteosarcoma AJCC v7, stage III soft tissue sarcoma AJCC v7, stage IV osteosarcoma AJCC v7, stage IV soft tissue sarcoma AJCC v7, stage IVA osteosarcoma AJCC v7, stage IVB osteosarcoma AJCC v7, and wilms tumor	Recruiting
NCT02122913	Larotrectinib	I	Unspecified adult solid tumor, protocol specific	Recruiting

NCT, National Clinical Trials.